Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate consisting of the monoclonal antibody trastuzumab linked to the maytansinoid DM1 with potential antineoplastic activity and is approved for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. An analysis of the US Fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samy Hakroush, Svenja Wulf, Julia Gallwas, Björn Tampe
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	focal segmental glomerulosclerosis collapsing FSGS tubular injury ado-trastuzumab emtansine T-DM1 acute kidney injury Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/69660472ecad4e3d87607bcd9af7c51b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69660472ecad4e3d87607bcd9af7c51b
record_format	dspace
spelling	oai:doaj.org-article:69660472ecad4e3d87607bcd9af7c51b2021-12-01T13:30:58ZCase Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy2234-943X10.3389/fonc.2021.796223https://doaj.org/article/69660472ecad4e3d87607bcd9af7c51b2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.796223/fullhttps://doaj.org/toc/2234-943XAdo-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate consisting of the monoclonal antibody trastuzumab linked to the maytansinoid DM1 with potential antineoplastic activity and is approved for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. An analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System identified 124/1,243 (10%) renal adverse events for trastuzumab. However, there are no published case reports describing kidney biopsy findings related to nephrotoxicity of either trastuzumab or T-DM1. We report kidney biopsy findings in a case of nephrotic range proteinuria due to collapsing focal segmental glomerulosclerosis (FSGS) and tubular injury after initiation of T-DM1 therapy. After systematic exclusion of other causes, it is likely that the observed collapsing FSGS was associated with the prior initiation of T-DM1 therapy. This is further supported by the clinical course with improvement of proteinuria and kidney function 3 weeks after discontinuation of T-DM1 therapy without further specific treatment. In summary, we provide the first report of kidney biopsy findings in a case of nephrotic range proteinuria after initiation of T-DM1 therapy due to collapsing FSGS. This issue is especially relevant since T-DM1 is widely used, and nephrologists have to be aware of this potentially rare but severe complication.Samy HakroushSvenja WulfJulia GallwasBjörn TampeFrontiers Media S.A.articlefocal segmental glomerulosclerosiscollapsing FSGStubular injuryado-trastuzumab emtansineT-DM1acute kidney injuryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	focal segmental glomerulosclerosis collapsing FSGS tubular injury ado-trastuzumab emtansine T-DM1 acute kidney injury Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	focal segmental glomerulosclerosis collapsing FSGS tubular injury ado-trastuzumab emtansine T-DM1 acute kidney injury Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Samy Hakroush Svenja Wulf Julia Gallwas Björn Tampe Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
description	Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate consisting of the monoclonal antibody trastuzumab linked to the maytansinoid DM1 with potential antineoplastic activity and is approved for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. An analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System identified 124/1,243 (10%) renal adverse events for trastuzumab. However, there are no published case reports describing kidney biopsy findings related to nephrotoxicity of either trastuzumab or T-DM1. We report kidney biopsy findings in a case of nephrotic range proteinuria due to collapsing focal segmental glomerulosclerosis (FSGS) and tubular injury after initiation of T-DM1 therapy. After systematic exclusion of other causes, it is likely that the observed collapsing FSGS was associated with the prior initiation of T-DM1 therapy. This is further supported by the clinical course with improvement of proteinuria and kidney function 3 weeks after discontinuation of T-DM1 therapy without further specific treatment. In summary, we provide the first report of kidney biopsy findings in a case of nephrotic range proteinuria after initiation of T-DM1 therapy due to collapsing FSGS. This issue is especially relevant since T-DM1 is widely used, and nephrologists have to be aware of this potentially rare but severe complication.
format	article
author	Samy Hakroush Svenja Wulf Julia Gallwas Björn Tampe
author_facet	Samy Hakroush Svenja Wulf Julia Gallwas Björn Tampe
author_sort	Samy Hakroush
title	Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
title_short	Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
title_full	Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
title_fullStr	Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
title_full_unstemmed	Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
title_sort	case report: collapsing focal segmental glomerulosclerosis after initiation of ado-trastuzumab emtansine therapy
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/69660472ecad4e3d87607bcd9af7c51b
work_keys_str_mv	AT samyhakroush casereportcollapsingfocalsegmentalglomerulosclerosisafterinitiationofadotrastuzumabemtansinetherapy AT svenjawulf casereportcollapsingfocalsegmentalglomerulosclerosisafterinitiationofadotrastuzumabemtansinetherapy AT juliagallwas casereportcollapsingfocalsegmentalglomerulosclerosisafterinitiationofadotrastuzumabemtansinetherapy AT bjorntampe casereportcollapsingfocalsegmentalglomerulosclerosisafterinitiationofadotrastuzumabemtansinetherapy
_version_	1718405121582301184

Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy

Ejemplares similares